Figure S3: 177Lu-DOTA Organ/tissue...
1
Figure S1: 177 Lu-DOTA organ/tissue biodistribution with and without clearing agent. Organ/tissue biodistribution (mean ± s.d., n=3) of 177 Lu-labeled DOTA at 24 h p.i. 500 ug Sm3e/C825 bsAb was injected followed by 250 ug Y-DOTA-dextran clearing agent 24 h later (+ clearing agent). No clearing agent was injected into control mice (- clearing agent). 100-150 μCi 177 Lu-DOTA was injected 1 h later. Figure S2: 111 In-DOTA-Dextran organ/tissue. Organ/tissue biodistribution (mean ± s.d., n=2) of 111 In-DOTA-Dextran at 4 h p.i. Figure S3: 177 Lu-DOTA Organ/tissue biodistribution. Organ/tissue biodistribution (mean ± s.d., n=3) of 177 Lu-labeled DOTA at 4, 24, and 48 h p.i. 500 ug Sm3e/C825 bsAb was injected followed by 250 ug Y-DOTA-dextran clearing agent 24 h later. 100- 150 μCi 177 Lu-DOTA was injected 1 h after the clearing agent.
Transcript of Figure S3: 177Lu-DOTA Organ/tissue...
Figure S1: 177Lu-DOTA organ/tissue biodistribution with and without clearing agent. Organ/tissue biodistribution (mean ± s.d., n=3) of 177Lu-labeled DOTA at 24 h p.i. 500 ug Sm3e/C825 bsAb was injected followed by 250 ug Y-DOTA-dextran clearing agent 24 h later (+ clearing agent). No clearing agent was injected into control mice (- clearing agent). 100-150 μCi 177Lu-DOTA was injected 1 h later. Figure S2: 111In-DOTA-Dextran organ/tissue. Organ/tissue biodistribution (mean ± s.d., n=2) of 111In-DOTA-Dextran at 4 h p.i. Figure S3: 177Lu-DOTA Organ/tissue biodistribution. Organ/tissue biodistribution (mean ± s.d., n=3) of 177Lu-labeled DOTA at 4, 24, and 48 h p.i. 500 ug Sm3e/C825 bsAb was injected followed by 250 ug Y-DOTA-dextran clearing agent 24 h later. 100-150 μCi 177Lu-DOTA was injected 1 h after the clearing agent.
